Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies

Current Drug Safety

Volumn 8, Issue 5, 2013, Pages 333-348

  Karlstad, Øystein ^a   Starup Linde, Jacob ^b,c   Vestergaard, Peter ^c,d   Hjellvik, Vidar ^a   Bazelier, Marloes T ^e   Schmidt, Marjanka K ^f   Andersen, Morten ^g   Auvinen, Anssi ^h   Haukka, Jari ⁱ   Furu, Kari ^a   de Vries, Frank ^e,j   de Bruin, Marie L ^e  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e UTRECHT UNIVERSITY   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g KAROLINSKA INSTITUTE   (Sweden)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Cancer risk; Diabetes mellitus; Insulin; Meta analysis; Neoplasm; Systematic review

Indexed keywords

ANTIDIABETIC AGENT; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE;

ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER RISK; CASE CONTROL STUDY; COLON CANCER; COLORECTAL CANCER; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EXPOSURE; DRUG USE; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LIVER CANCER; MELANOMA; META ANALYSIS; OBSERVATIONAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT CANCER; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; NEOPLASMS; OBSERVATIONAL STUDY AS TOPIC; PUBLICATION BIAS; REGISTRIES; RESEARCH DESIGN;

EID: 84891507550     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15680266113136660067     Document Type: Article

References (83)

1. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-23.
2. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and Cancer: A consensus report. Diabetes Care 2010; 33: 1674-85.
3. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010; 47: 87-95.
4. Pollak M, Russell-Jones D. Insulin analogs and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 2010; 64: 628-36.
5. Home P. Insulin Therapy and Cancer. Diabetes Care 2013; 36: S240-S244.
6. DeCensi A, Puntoni M, Goodwin P, et al. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. Cancer Prevent Res 2010; 3: 1451-61.
7. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type-2 diabetes: A systematic review and metaanalysis. Diabet & Metabol 2012; 38: 475-84.
8. Soranna D, Scotti L, Zambon A, et al. Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. Oncologist 2012; 17: 813-22.
9. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-708.
10. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009; 374: 511-3.
11. Gale EA. Insulin glargine and cancer: another side to the story? Lancet 2009; 374: 521.
12. Hernández-Díaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 2010; 53: 802-8.
13. Renehan AG. Insulin analogs and cancer risk: the emergence of second-generation studies. Diabetologia 2012; 55: 7-9.
14. Suissa S, Azoulay L. Metformin and the Risk of Cancer: Timerelated biases in observational studies. Diabetes Care 2012; 35: 2665-73.
15. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52: 2499-506.
16. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard TM. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009; 52: 2507-12.
17. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New Engl J Med 2012; 367: 319-28.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: e1000097.
19. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org. 2011.
20. Karlstad Ø, Hjellvik V, Furu K, et al. Use of insulin and insulin analogs and risk of cancer. PROSPERO 2012: CRD42012002428. PROSPERO International prospective register of systematic reviews 2013; cited 2013 Oct 20: Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CR D42012002428.
21. Starup-Linde J, Karlstad O, Aistrup Eriksen S, et al. CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants-a Systematic Review and a Meta-Analysis. Curr Drug Saf 2013; 8: 296-332.
22. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute (OHRI) 2013; Available from: http://www.ohri.ca/Programs/clinical_epidemiolog y/oxford.asp
23. Böhning D. Computer-assisted analysis of mixtures and applications: meta-analysis, disease mapping and others. Monographs on statistics and applied probability. Boca Raton, FL: Chapman & Hall/CRC; 2000. p. 1-232.
24. Matthias E, George DS, Martin S, Christoph M. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
25. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, et al. Insulin glargine and risk of cancer: A cohort study in the French National Healthcare Insurance Database. Diabetologia 2012; 55: 644-53.
26. Campbell PT, Deka A, Jacobs EJ, et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 2010; 139: 1138-46.
27. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012; 55: 948-58.
28. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin Glargine among adult type 2 diabetes patients-a nationwide Cohort study. PLoS ONE 2011; 6: e21368.
29. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755-65.
30. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
31. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care 2012; 10: doi: 10.2337/dc12-0506.
32. Ferrara A, Lewis JD, Quesenberry CP, et al. Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes. Diabetes Care 2011; 34: 923-9.
33. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-44.
34. Hense HW, Kajuter H, Wellmann J, Batzler W. Cancer incidence in type 2 diabetes patients-first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr 2011; 3: 15.
35. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Dia Res 2012; 2012: 413782.
36. Kostev K. Risk of breast cancer in patients on long-acting insulin analogs in comparison with those on human insulin. Diabetologia 2012; 55: 1554-5.
37. Lai HC, Tsai IJ, Chen PC, et al. Gallstones, a cholecystectomy, chronic pancreatitis, and the risk of subsequent pancreatic cancer in diabetic patients: a population-based cohort study. J Gastroenterol 2012; 48(6): 721-7.
38. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DPH, Chen CC. Antidiabetes Drugs Correlate With Decreased Risk of Lung Cancer: A Population-Based Observation in Taiwan. Clin Lung Cancer 2012; 13: 143-8.
39. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: A population-based cohort study. Am J Gastroenterol 2012; 107: 46-52.
40. Lind M, Fahlen M, Eliasson B, Oden A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 2012; 6: 53-9.
41. Ljung R, TalbAck M, Haglund B, Jonasson JM, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-A three-year population-based observation. Acta Oncol 2011; 50: 685-92.
42. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: A retrospective cohort study of older medicare patients. Diabetes Care 2011; 34: 1965-71.
43. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia 2012; 55: 1953-62.
44. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer 2013; 132: 2186-91.
45. Oliveria SA, Koro CE, Ulcickas YM, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr Clin Res Rev 2008; 2: 47-57.
46. Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control 2012; 23: 1785-95.
47. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogs in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012; 55: 51-62.
48. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011; 54: 2254-62.
49. Tseng CH. Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan. Ann Oncol 2012; 23: 153-8.
50. Van Staa TP, Patel D, Gallagher AM, De Bruin ML. Glucoselowering agents and the patterns of risk for cancer: A study with the General Practice Research Database and secondary care data. Diabetologia 2012; 55: 654-65.
51. Yang X, Ko GTC, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: The Hong Kong diabetes registry. Diabetes 2010; 59: 1254-60.
52. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33: 1304-8.
53. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: A case-control analysis. Gynecol Oncol 2011; 123: 200-4.
54. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin is not associated with a decreased risk of colorectal cancer: A case-control analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 280-6.
55. Bodmer M, Becker C, Jick SS, Meier CR. Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer 2012; 78: 133-7.
56. Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: A case-control study in Northern Italy. Pancreas 2003; 27: 143-9.
57. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Arnold CK. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462-72.
58. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: E1170-E1175.
59. Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control 2012; 23: 1193-203.
60. Fortuny J, Benavente Y, Bosch R, Garcia-Villanueva M, de Sevilla AF, De SS. Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer 2005; 41: 1782-7.
61. Kawaguchi T, Taniguchi E, Morita Y, et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010; 30: 479-86.
62. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 485-92.
63. Li D, Tang H, Hassan M, Holly E, Bracci P, Silverman D. Diabetes and risk of pancreatic cancer: a pooled analysis of three large casecontrol studies. Cancer Causes Control 2011; 22: 189-97.
64. Mizuno S, Nakai Y, Isayama H, et al. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. J Gastroenterol 2013; 48: 238-46.
65. Vinikoor LC, Long MD, Keku TO, Martin CF, Galanko JA, Sandler RS. The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. Cancer Epidemiol Biomarkers Prev 2009; 18: 1239-42.
66. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-50.
67. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: A cohort study in the french national healthcare insurance database. Fund Clin Pharmacol 2012; 26: 1-122.
68. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-8.
69. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830-7.
70. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-54.
71. Ljung R, Talback M, Haglund B, Jonasson JM, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of breast cancer-a four-year population-based observation. Acta Oncol 2012; 51: 400-2.
72. Liao KF, Lai SW, Li CI, Chen WC. Diabetes mellitus correlates with increased risk of pancreatic cancer: A population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012; 27: 709-13.
73. Liao KF, Lai SW, Li CI. The impact of anti-diabetic drugs on colorectal cancer risk in a large cohort of women with diabetes. Libyan J Med 2012; 7: doi: 10.3402/ljm.v7i0.17532.
74. Monami M, Lamanna C, Pala L, et al. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. Exp Clin Endocrinol Diabetes 2008; 116: 184-9.
75. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46: 279-84.
76. Buchs AE, Silverman BG. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: A historical cohort study. Metabolism 2011; 60: 1379-85.
77. Chuang TY, Lewis DA, Spandau DF. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using insulin: a pilot study. Brit J Dermatol 2005; 153: 552-7.
78. Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3025-32.
79. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case-Control Analysis. Am J Gastroenterol 2012; 107: 620-6.
80. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogs and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010; 33: 1997-2003.
81. Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011; 54: 2263-71.
82. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52: 1971-3.
83. Carstensen B. Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry. Diabetes 2010; 59: e17-e18.